Gilead Sciences  2Q Revenues: $1.3 billion, (+22%) 2Q Earnings: $442.8 million (+9%)* YTD Revenues: $2.5 billion (+22%) YTD Earnings: $939.0 million (+15%) Comments: Product sales were a record $1.2 billion in the quarter driven by the antiviral franchise ($1.1 billion, up 34%), including the strong growth of Atripla and continued growth of Truvada. Atripla sales were $355.1 million (+67%) and Truvada sales were $516.1 million (+34%). R&D expenses in the quarter were $176.5 m...